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Abstract: This study was designed to investigate the therapeutic effect of novel compound Z-9-octadecenyl-       
2-propanesulfonamide (N15) on diabetes-associated cognitive decline (DACD).  Type 2 diabetes (T2DM) mice 
models were established with multiple injection of low doses of streptozotocin (STZ) in mice on high fat diet 
(HFD).  Vehicle and different concentrations of N15 (50 and 100 mg·kg−1·d−1) were administrated orally for       
6 weeks.  The step-down test, dark avoidance task and Morris water maze were conducted at the 6th week.  The 
level of glucose and lactic acid in hippocampus were determined and mRNA of growth associated protein-43 
(GAP-43), synaptophysin (SYN), brain derived neurotrophic factor (BDNF) and neurotrophins-3 (NT-3) in       
hippocampus were analyzed by real time PCR.  The beneficial effects of N15 on learning and memory were 
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found in the test of step-down, dark avoidance and Morris water maze.  N15 reduced the level of glucose and 
lactic acid in hippocampus of HFD+STZ-induced diabetic encephalopathy model mice.  Additionally, the 
mRNA expression of GAP-43, SYN, BDNF and NT-3 in hippocampus of HFD+STZ-induced diabetic encepha-
lopathy mice were significantly increased by N15 (P<0.01).  These results suggest that the novel compound 
N15 can ameliorate diabetes-associated cognitive decline and the potential mechanism may be associated with 
the expressions of increased synaptic-related factors and neurotrophic factor in the hippocampus of diabetes-       
associated cognitive decline in mice. 
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Table 1  Primer sequences used for qPCR.  GAP-43: Growth associated protein-43; SYN: Synaptophysin; BDNF: Brain derived neurotrophic factor; 
NT-3: Neurotrophins-3 
Gene Primer sequence (5'→3') Primer sequence (3'→5') 
GAP-43 GCTAGCTTCCGTGGACACAT CTTCTCCACACCATCAGCAA 
SYN TCCTCGGCTGAATTCTTTGT TTGGCCCTTTGTTGTTCTCT 
BDNF GTAAACGTCCACGGACAAGG AGTGTCAGCCAGTGATGTCG 
NT-3 TGCAACGGACACAGAGCTAC TTGCCCACATAATCCTCCAT 




Figure 2  Effect of N15 on escaping reaction acquisition in 
step-down test and dark avoidance task of the streptozotocin 
(STZ)-induced diabetic encephalopathy (DE) model mice.  DE 
mice were treated with saline or N15 at doses of 50 or 100 
mg·kg−1 once a day for 6 weeks.  The step-down test and dark 
avoidance task was measured at the 6th week.  A: The latency 
time of step-down tests; B: The diving times of step-down tests; 
C: The latency time of dark avoidance task; D: The diving times 
of dark avoidance task.  Mean ± SEM, n = 10.  #P < 0.05, ##P < 
0.01 vs normal group; *P < 0.05, **P < 0.01, ***P < 0.001 vs DE 
group 
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Figure 3  Beneficial effects of N15 on learning and memory in HFD+STZ-induced DE model mice.  DE mice were treated with saline 
or N15 at doses of 50 or 100 mg·kg−1 once a day for 6 weeks.  The Morris water maze was measured at the 6th week.  A: Representa-
tive path traces in each quadrant during the probe trail; B: The escape latency during acquisition training; C: The crossing times in the 
hidden platform trails; D: The time spent in the target quadrant; E: The distance spent in the target quadrant; F: The time spent in the 
target; G: the distance spent in the target.  Mean ± SEM, n = 10.  #P < 0.05, ##P < 0.01 vs normal group; *P < 0.05, **P < 0.01 vs DE group 
 




Figure 4  Effect of N15 on the level of glucose and lactic acid 
in hippocampus of HFD+STZ-induced DE model mice.  DE mice 
were treated with saline or N15 at doses of 50 or 100 mg·kg−1 once 
a day for 6 weeks.  The level of glucose (A) and lactic acid (B) 
were measured at the 6th week.  Mean ± SEM, n = 10.  ###P < 
0.001 vs normal group; *P < 0.05, **P < 0.01 vs DE group 
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Figure 5  Effect of N15 on the mRNA expression of GAP-43, SYN, BDNF and NT-3 in hippocampus of HFD+STZ-induced DE model 
mice.  DE mice were treated with saline or N15 at doses of 50 or 100 mg·kg−1 once a day for 6 weeks.  The values are expressed as 
percentages compared with the normal group (set to 100%).  Mean ± SEM, n = 10.  ##P < 0.01, ###P < 0.001 vs normal group; *P < 0.05, 
**P < 0.01, ***P < 0.001 vs DE group 
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